EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. ...